Pfizer Shuffle: Simmons Out, Brandicourt In At Emerging Markets And Established Products Unit
This article was originally published in PharmAsia News
David Simmons, head of established products and emerging markets at Pfizer, has jumped ship to lead global CRO PPD Inc. Olivier Brandicourt, currently head of primary care at the big pharma, will take Simmons’ place.
You may also be interested in...
Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.
Two private equity firms’ agreement to acquire Pharmaceutical Product Development Inc. and take the company private is the latest and largest deal in a recent spate of PE activity among contract research organizations – and perhaps not the last, or even least.
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.